Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | GPR6 | P46095 | 4/20 | 0.38 |
| ▸ | FPR2 | P25090 | 2/20 | 0.38 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.36 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.36 |
| ▸ | BCL6 | P41182 | 1/20 | 0.35 |
| ▸ | GALR1 | P47211 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4836323 | 0.90 | FPR2 (0.45) | PIK3CDGPR6FPR2PROKR1 | |
| SCHEMBL4829561 | 0.84 | EHMT2 (0.46) | PIK3CDGPR6FPR2PROKR1KDM4E | |
| SCHEMBL4829397 | 0.82 | EHMT2 (0.42) | PIK3CDGPR6FPR2PROKR1EHMT2 | |
| SCHEMBL6209284 | 0.79 | PDGFRB (0.39) | PIK3CDGPR6FPR2PROKR1KMT2A | |
| SCHEMBL4829119 | 0.78 | SRC (0.44) | BCL6 | |
| SCHEMBL5431636 | 0.75 | GALR1 (0.49) | KCNH2EHMT2BCL6GALR1 | |
| SCHEMBL5441787 | 0.75 | FAAH (0.40) | PIK3CDFPR2PROKR1 | |
| SCHEMBL4829420 | 0.75 | DRD2 (0.45) | KCNH2GALR1 | |
| SCHEMBL4833030 | 0.73 | BCL6 (0.51) | HTTKMT2AMEN1EHMT2EHMT1 | |
| SCHEMBL6234397 | 0.73 | EHMT2 (0.53) | KDM4EALDH1A1EHMT2EHMT1BCL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169784-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20050137196-A1 | Medical devices employing triazine compounds and compositions thereof | NATIONAL BANK OF CANADA (CA) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137196-A1 | Medical devices employing triazine compounds and compositions thereof | PTGIS, AREG, TGFB1 | PIK3CD 1898/4885GPR6 1040/4885FPR2 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.